Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. May 15, 2022; 14(5): 1002-1013
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.1002
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.1002
Figure 1 Kaplan-Meier survival estimates between subgroups according to albumin-to-alkaline phosphatase ratio.
A: Overall survival (OS) according to albumin-to-alkaline phosphatase ratio (AAPR) before propensity matching; B: Progression-free survival (PFS) according to AAPR before propensity matching; C: OS according to AAPR after propensity matching; D: PFS according to AAPR after propensity matching. AAPR: Albumin-to-alkaline phosphatase ratio.
- Citation: Li YT, Zhou XS, Han XM, Tian J, Qin Y, Zhang T, Liu JL. Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer. World J Gastrointest Oncol 2022; 14(5): 1002-1013
- URL: https://www.wjgnet.com/1948-5204/full/v14/i5/1002.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i5.1002